Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Prevention of respiratory syncytial virus infection in infants.

× No keyword cloud information.

10 in total

1. Contribution of RSV to bronchiolitis and pneumonia-associated hospitalizations in English children, April 1995-March 1998.

Authors: B Müller-Pebody; W J Edmunds; M C Zambon; N J Gay; N S Crowcroft
Journal: Epidemiol Infect Date: 2002-08 Impact factor: 2.451

Review 2. Clinical experience with respiratory syncytial virus vaccines.

Authors: Pedro A Piedra
Journal: Pediatr Infect Dis J Date: 2003-02 Impact factor: 2.129

3. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine.

Authors: H W Kim; J G Canchola; C D Brandt; G Pyles; R M Chanock; K Jensen; R H Parrott
Journal: Am J Epidemiol Date: 1969-04 Impact factor: 4.897

4. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.

Authors:
Journal: Pediatrics Date: 1998-09 Impact factor: 7.124

Review 5. Basic epidemiology and immunopathology of RSV in children.

Authors: J Handforth; J S Friedland; M Sharland
Journal: Paediatr Respir Rev Date: 2000-09 Impact factor: 2.726

6. Bovine parainfluenza virus type 3 (PIV3) expressing the respiratory syncytial virus (RSV) attachment and fusion proteins protects hamsters from challenge with human PIV3 and RSV.

Authors: Aurelia A Haller; Misrach Mitiku; Mia MacPhail
Journal: J Gen Virol Date: 2003-08 Impact factor: 3.891

7. Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women.

Authors: Flor M Munoz; Pedro A Piedra; W Paul Glezen
Journal: Vaccine Date: 2003-07-28 Impact factor: 3.641

8. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease.

Authors: Timothy F Feltes; Allison K Cabalka; H Cody Meissner; Franco M Piazza; David A Carlin; Franklin H Top; Edward M Connor; Henry M Sondheimer
Journal: J Pediatr Date: 2003-10 Impact factor: 4.406

9. The reducing incidence of respiratory tract infection and its relation to antibiotic prescribing.

Authors: Douglas M Fleming; Andrew M Ross; Kenneth W Cross; Helen Kendall
Journal: Br J Gen Pract Date: 2003-10 Impact factor: 5.386

10. Current approaches to the development of vaccines against disease caused by respiratory syncytial virus (RSV) and parainfluenza virus (PIV). A meeting report of the WHO Programme for Vaccine Development.

Authors: J E Crowe
Journal: Vaccine Date: 1995-03 Impact factor: 3.641

10 in total

5 in total

Review 1. Palivizumab for preterm infants. Is it worth it?

Authors: N D Embleton; C Harkensee; M C Mckean
Journal: Arch Dis Child Fetal Neonatal Ed Date: 2005-07 Impact factor: 5.747

2. Epidemiology of respiratory syncytial virus in children ≤2 years of age hospitalized with lower respiratory tract infections in the Russian Federation: a prospective, multicenter study.

Authors: Vladimir Tatochenko; Vasily Uchaikin; Aleksandr Gorelov; Konstantin Gudkov; Andrew Campbell; Gregory Schulz; Rebecca Prahl; Gerard Notario
Journal: Clin Epidemiol Date: 2010-10-21 Impact factor: 4.790

3. Severe respiratory syncytial virus infections and reduced interferon-gamma generation in vitro.

Authors: U Schauer; S Hoffjan; T Rothoeft; H Bartz; S Konig; E Fuchs; J Bittscheidt; A Kochling; V Stephan
Journal: Clin Exp Immunol Date: 2004-10 Impact factor: 4.330

4. Comparison of risk factors between preterm and term infants hospitalized for severe respiratory syncytial virus in the Russian Federation.

Authors: Katherine L Gooch; Gerard F Notario; Gregory Schulz; Konstantin M Gudkov; Katharina Buesch; Hoa Khong; Andrew Campbell
Journal: Int J Womens Health Date: 2011-05-06

5. T cell receptor signaling pathway and cytokine-cytokine receptor interaction affect the rehabilitation process after respiratory syncytial virus infection.

Authors: Zuanhao Qian; Zhenglei Zhang; Yingying Wang
Journal: PeerJ Date: 2019-06-12 Impact factor: 2.984

5 in total